Kolon Life Sciences announced on March 11 that it has obtained U.S. Food and Drug Administration (FDA)’s investigational new drug (IND) approval for phase 1 and phase 2a clinical trials of KLS-2031, a gene therapy for neuropathic pain.
KLS-2031 is a pipeline succeeding the world's first osteoarthritis cell gene therapy Invossa and is an injection type of gene therapy, different from the conventional neuropathic pain treatment methods.
Neuropathic pain refers to pain caused by damage or functional abnormality of the nervous system instead of the body. It is intractable and tends to be chronic. It is a sensory neurological disorder that causes extreme pain for patients, while the stimuli are barely detectable in normal people.
The procedure is designed to promote long-term analgesic effects with a singlelocal injection and targets patients with neuropathic pain, who found conventional treatments ineffective.